BOLD Receives Cannabis Oil Sales License From Health Canada
SASKATOON–BOLD Growth Inc., a licensed producer based in Saskatchewan is pleased to announce it has been granted a license from Health Canada to sell cannabis oil products, effective May 12, 2021. This license will allow BOLD to continue expanding their craft product offerings into new categories such as vapes, edibles, topicals and extracts. The company plans to start off by releasing vape products in the coming months to excite the craft cannabis consumer. BOLD’s oil products will be produced, packaged and distributed to provinces from its Saskatoon, Saskatchewan facility.
“We have been receiving an amazing response to our flower and pre-rolled products, and we’re looking forward to offering a more diverse range of products to give our consumers greater choice,” says Andrew Condin, CEO of BOLD. “Craft quality products continue to be in high demand, and we are eager to start supplying the retail market with the products we have been formulating in anticipation of this licensing achievement.”
BOLD also plans to further commercialize its patent pending extraction technology to develop CBD and THC rich oils for the edible and topical markets. This proprietary method pulls cannabinoids from fresh, undried, plant material using a food grade oil, allowing for cost effective scalability.
“Our industry currently relies on extensive drying & milling of cannabis prior to extraction. The technology in our proprietary method relies on extraction using a non-volatile oil that is well known to the food, pharma and topical industries. This enables us to skip the drying step and perform extractions at room temperature & pressure without extensive engineering controls,” stated Dr. Brent Pollock, Downstream Processing Manager.
(This information is primarily sourced from Bold. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...